ERBB2 and breast carcinoma: Further supporting that CDCP1 is important in breast cancer resistance to trastuzumab, a more recent study demonstrated that CDCP1 and HER2 are co-overexpressed in 12% of primary and 30% of metastatic breast tumors, and that co-expression correlates with poorest disease free and overall survival [21].